Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 18/20 | 0.64 |
| ▸ | KLK1 | P06870 | 11/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16486491 | 0.89 | KLKB1 (0.63) | KLKB1KLK1 | |
| SCHEMBL16487373 | 0.86 | KLKB1 (0.62) | KLKB1KLK1 | |
| SCHEMBL29779637 | 0.82 | KLKB1 (0.61) | KLKB1KLK1NR1I2KCNH2GRM2 | |
| SCHEMBL28052880 | 0.80 | KLKB1 (0.52) | KLKB1KLK1 | |
| SCHEMBL16486732 | 0.79 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL29779639 | 0.79 | KLKB1 (0.63) | KLKB1KLK1NR1I2KCNH2GRM2 | |
| SCHEMBL16486402 | 0.78 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL17818636 | 0.77 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL17696410 | 0.75 | KLKB1 (0.55) | KLKB1KLK1 | |
| SCHEMBL16486446 | 0.75 | KLKB1 (0.58) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885KLK1 4/4885CYP11B1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.